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Abstract
Background: Arthroscopic subacromial decompression (ASAD) is a commonly performed surgical intervention for
shoulder pain. The rationale is that removal of a bony acromial spur relieves symptoms by decompressing rotator
cuff tendons passing through the subacromial space. However, the efficacy of this procedure is uncertain. The
objective of this trial was to compare the efficacy and cost-effectiveness of ASAD in patients with subacromial pain
using appropriate control groups, including placebo intervention.
Methods/Design: The trial is a three-group, parallel design, pragmatic, randomised controlled study. The intervention
content for each group (ASAD, active monitoring with specialist reassessment (AMSR) and investigational shoulder
arthroscopy only (AO)) enables assessment of (1) the efficacy of the surgery against no surgery; (2) the need for a specific
component of the surgery—namely, removal of the bony spur; and (3) quantification of the placebo effect. Concealed
allocation was performed using a 1:1:1 randomisation ratio and using age, sex, baseline Oxford Shoulder Score (OSS) and
centre as minimisation criteria. The primary outcome measure is the OSS at 6 months post randomisation. A total of 300
patients recruited over 24 months from a minimum of 14 UK shoulder units over 24 months were required to detect a
difference of 4.5 points on the OSS (standard deviation, 9) with 90% power and to allow for 15% loss to follow-up.
Secondary outcomes include cost-effectiveness, pain, complications and patient satisfaction. A substantial qualitative
research component is included. The primary analysis will be conducted on the modified intention-to-treat analysis.
Sensitivity analysis will be used to assess the robustness of the results with regard to the underlying assumptions about
missing data using multiple imputation.
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Discussion: This trial uses an innovative design to account for the known placebo effects of surgery, but it also will
delineate the mechanism for any benefit from surgery. The investigational AO group is considered a placebo intervention
(not sham surgery), as it includes all components of subacromial decompression except the critical surgical element.
Some discussion is also dedicated to the challenges of conducting placebo surgery trials.
Trial registrations: UK Clinical Research Network UKCRN12104. Registered 22 May 2012.
International Standard Randomised Controlled Trial ISRCTN33864128. Registered 22 June 2012.
ClinicalTrials.gov NCT01623011. Registered 15 June 2012.
Keywords: Acromion, Arthroscopy, Placebo, Randomise, Sham, Shoulder, Trial, Waiting list
Background
The prevalence of shoulder complaints in the United
Kingdom is estimated to be 14%, with 1% to 2% of adults
consulting their general practitioner annually regarding
new-onset shoulder pain [1]. Rotator cuff pathology, in-
cluding rotator cuff tears and subacromial pain, report-
edly accounts for up to 70% of shoulder pain problems
[2]. Other common causes of shoulder pain include fro-
zen shoulder, calcific tendonitis and osteoarthritis (OA).
Painful shoulders pose a substantial socioeconomic
burden. Disability of the shoulder can impair ability to
work or perform household tasks [3] and can result in
time off work [4]. Shoulder problems account for 2.4%
of all general practitioner consultations in the United
Kingdom [5] and 4.5 million visits to physicians annually
in the United States [6]. With the exception of fractures
and traumatic rotator cuff tears, most shoulder pain
problems are treated initially with conservative care. In
some patients with persistent symptoms, surgery may be
required. More than 300,000 surgical repairs for rotator
cuff pathologies are performed annually in the United
States, and the annual financial burden of shoulder pain
management in the United States has been estimated to
be US$3 billion [7].
Subacromial pain is the most frequent cause of shoul-
der problems in the general population. An anatomic
aetiology has been proposed whereby mechanical con-
tact occurs between the rotator cuff tendons and the
overlying acromion and coracohumeral ligament. Suba-
cromial pain and rotator cuff tears are associated with
progressive change in the shape of the acromion, with
‘spurs’ forming at its anteroinferior margin. Evidence
suggests spurs develop which narrow the subacromial
space, thereby making physical contact more likely, par-
ticularly in certain positions of the arm (known as a
‘painful arc’), and resulting in inflammation [8,9]. This
is sometimes referred to as impingement. However, this
term suggests a definitive mechanism of the pain, and
conflicting theories indicate that such mechanisms do
not fully explain all shoulder pain. For the purposes of
the present study, we will continue to refer to this as
subacromial pain.
A high proportion of patients with subacromial pain re-
spond to conservative treatment alone [10]. The most fre-
quent indications for surgery are persistent and severe
pain combined with functional restrictions that are resist-
ant to conservative measures. Some reports suggest that
surgery may be no more effective than physiotherapy in
the relief of pain after variable attempts at conservative
care. Contradicting these reports are cohort studies de-
scribing good outcome after surgery [11,12]. The most
common surgical intervention for subacromial pain is a
subacromial decompression (SAD), which can be per-
formed using an arthroscopic SAD (ASAD) approach. An
assessment of the cost of treatment of impingement also
suggested that the addition of surgery, in comparison to
exercise treatment alone, is not cost-effective [13].
Further research should aim to identify whether re-
moval of subacromial spurs associated bursa and release
of the coracoacromial ligament is beneficial, which
would thereby help to rationalise surgical treatment.
Rotator cuff tears
One possible cause of subacromial pain is a rotator cuff
tear. The term rotator cuff tear refers to structural fail-
ure and tissue disruption in at least one of the four mus-
cles and tendons that form the rotator cuff. Any tear
that involves rotator cuff disruption that does not extend
all the way through the tendon is termed a partial
thickness tear (PTT). PTTs are more prevalent than full-
thickness tears [14]. Information is lacking regarding the
risk of progression of PTTs to full-thickness tears, al-
though it is suggested that lesions involving more than
50% of the thickness of the cuff are at risk of progression
in the long term [15]. The management of PTTs is con-
troversial, and patients with PTTs have commonly been
treated conservatively. If the symptoms fail to resolve
with conservative treatment, then ASAD might be bene-
ficial. Favourable results have been reported following
debridement of PTT in association with ASAD [16].
Subacromial decompression surgery
It is widely assumed that arthroscopic SAD (ASAD) has
some therapeutic benefit. This assumption is based on
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the belief that much of the pain and symptoms of suba-
cromial pain is due to mechanical contact between the
upper surface of the rotator cuff tendons and the under-
surface of the acromion. This pain is also thought to be
associated with inflammation of the intervening subacro-
mial bursa.
ASAD has been performed for the treatment of suba-
cromial pain and rotator cuff disease for the last 35
years. The number of ASADs performed by orthopaedic
surgeons has increased significantly over time, a fact
made remarkable by the absence of any compelling or
concrete evidence in support of the procedure. A 254%
increase between 1996 and 2006 (from 29.9 to 102.2 per
100,000 people per year) in use of the procedure in New
York State was reported, with only a 74% increase in
orthopaedic surgery overall and a 475% increase (from
3.3 to 19.0 per 100,000 people per year) in use of the
procedure in Olmsted County, Minnesota, in the 25
years leading up to 2005 [17,18]. Although both studies
showed a significant increase in use of the procedure,
the New York State surgeons performed over five times
as many decompressions per capita as their colleagues in
Rochester, Minnesota.
The introduction of less invasive arthroscopic tech-
niques accounts for some of the overall increased rate
of surgery, but it does not explain the geographic vari-
ation. Patient and disease characteristics have not chan-
ged over time, and there is a growing concern that this
procedure is being overused. Observational studies of
ASAD show positive results in terms of pain reduction
and functional outcome, with high patient satisfaction
rates. However, equally good outcomes have been noted
in two studies in which researchers followed patients
who had arthroscopic rotator cuff debridement or open
rotator cuff repair in the absence of SAD [19,20]. Fur-
thermore, comparative studies of ASAD versus nonop-
erative treatment options, such as physiotherapy, have
not shown any significant difference in outcomes be-
tween the two treatment modalities [21-26]. There are
a number of studies in which investigators have tried to
assess the effectiveness of SAD in comparison with a
control. In an important, recently reported randomised
controlled trial (RCT), ASAD plus subacromial bursect-
omy was compared with bursectomy alone, and the re-
searchers reported no significant difference in clinical
outcomes between the two groups. This finding sug-
gests that removing acromial spurs might not be neces-
sary [27].
Such studies support the theory that undergoing a sur-
gical intervention for subacromial pain carries a signifi-
cant placebo effect and that removal of the subacromial
spur of bone may not be necessary. Unfortunately, no
RCTs have been performed on patients with subacromial
pain to show that ASAD is more effective than simply
inserting the arthroscope, as per investigative arthros-
copy, or doing nothing at all (no treatment). The UK
Database of Uncertainties about the Effects of Treatment
confirms the lack of evidence. It highlights the low level
of evidence available and the high susceptibility of bias
which exists in some of the publications on this topic.
Therefore, we remain ignorant of the mode of action of
any potential therapeutic effect. All three options have
yet to be tested satisfactorily [28-33].
Methods/Design
Ethical approval
UK National Health Service (NHS) ethical approval was
obtained on 2 February 2012 from the National Research
Ethics Service (NRES) South Central–Oxford B Research
Ethics Committee (REC) (12/SC/0028). Local NHS re-
search and development approvals have been gained for
each recruiting centre. The study has been accepted on
to the UK Clinical Research Network portfolio.
Concept
The trial is a three-group, parallel, pragmatic RCT. By
performing three two-way comparisons, we will test dif-
ferences between groups. Patients will be randomised in
a 1:1:1 ratio. Blinding will be performed for both patients
and post intervention assessors in each of the surgical
interventions groups (ASAD and arthroscopy-only (AO)
groups). Blinding of the assessors will be possible only
for the active monitoring with specialist reassessment
(AMSR) group.
The first null hypothesis for this trial is that there is
no difference between ASAD and AMSR in patients for
whom conservative care has failed. AMSR involves no
surgical treatment, and the patients who receive it will
be considered the control group in this comparison. If
this null hypothesis is rejected, with ASAD showing
benefit, then ASAD may be an effective treatment. If this
null hypothesis cannot be rejected, then ASAD may be
ineffective, and its continued use as a surgical interven-
tion should be questioned.
However, there is also a need to understand how po-
tential treatment differences are achieved, notably
whether removal of the bone spur is necessary during
surgery or whether undergoing arthroscopic shoulder
surgery alone (without bony excision) produces similar
effects. Further comparisons, including the use of a pla-
cebo surgical intervention, will provide this information.
A second null hypothesis is that there is no difference
between ASAD and AO in patients for whom conserva-
tive care has failed. If this null hypothesis cannot be
rejected (or in the unlikely event of the AO group show-
ing greater benefit), then the study may indicate that the
proposed critical surgical element—removal of the bone
spur—is not necessary to achieve a treatment effect.
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Should the hypothesis be rejected (with ASAD having
greater benefit), then bone removal can be deemed ne-
cessary and can be identified as a critical element of sur-
gery. The mechanism will be delineated, and a greater
understanding of the mechanical requirements of the
surgery will be obtained. Furthermore, this comparison
introduces placebo as an important factor in the design,
with the specific relevance and influence of placebo de-
tailed subsequently.
The third and final comparison will be between the
AO and AMSR groups, in which the value of surgery
will be quantified, be it in the form of placebo effect
or true physiological effects. An inability to reject the
null hypothesis for AO versus AMSR will suggest that
arthroscopy, without bone removal, has no significant
clinical benefit. In contrast, rejection of the null hy-
pothesis in favour of AO over AMSR will indicate that
some form of surgery, be it placebo effect or not, can
produce useful treatment effects compared with sim-
ple monitoring.
As this design is innovative and involves placebo as-
pects, more detailed reasoning for the comparisons is
given below.
The first comparison testing for treatment efficacy of
ASAD against no treatment is straightforward. In the
trial, we will examine standard care (theoretically the
treatment of choice—ASAD) against no surgical inter-
vention, and the trial will provide a clear answer to the
question of treatment efficacy of routinely performed
ASAD.
To identify which aspect of the surgery produces bene-
fit, there is a need to take account of any placebo effects
of the operation. This requires the introduction of a
sham or placebo component. Unlike other well-known
placebo or sham surgery trials, such as the Moseley et
al. knee trial for OA [28],(in which arthroscopic lavage/
debridement was shown to be no better than an entirely
sham operative procedure, the placebo for the Can
Shoulder Arthroscopy Work? (CSAW) Study is not
sham surgery, but rather a placebo intervention. A pla-
cebo surgical intervention is a surgical treatment which
contains all components of the surgical procedure under
investigation in an identical sequence, but with the ac-
tive or critical part of the procedure omitted. We have
defined this as the critical surgical element [29]. In our
CSAW example, the AO group will have surgery that
contains all components of the standard ASAD proced-
ure, but without removal of the bony spur.
The third comparison between AO and active moni-
toring is less consequential in terms of changing prac-
tice, but it does provide further insight into how
shoulder surgery for acromial pain achieves any benefit.
Any observed differences found in favour of AO over
AMSR (the control) would enable the improvement to
be attributed to either (1) the more general effects of
arthroscopic shoulder surgery (but not bone removal) or
(2) the placebo effect associated with undergoing surgery.
In summary of the concept, the proposed critical sur-
gical element in this trial is removal of the bone spur–
associated bursal tissue and release of the coracoacro-
mial ligament. The design of the trial not only tests the
efficacy of surgery but also, by accounting for the likely
placebo effect associated with undergoing surgery, allows
the true therapeutic mechanism of the surgery to be
identified.
Qualitative study
Recruitment in many RCTs is challenging because of dif-
ficulties in explaining and justifying to patients the con-
cepts inherent in the design (such as randomisation and
uncertainty) and because many contemporary RCTs re-
quire comparison of very different interventions (such as
surgical and nonsurgical treatments) [30]. There is a
dearth of robust evidence about effective strategies to
improve recruitment into RCTs [31]. However, qualita-
tive research has been used to understand recruitment
into specific RCTs [32-36] and has been shown to im-
prove recruitment in some cases [37,38]. A qualitative
recruitment investigation (QRI) will be integrated into
the CSAW Study to identify sources of recruitment diffi-
culties and to suggest changes to improve levels of in-
formed consent and randomisation.
The QRI will monitor recruitment into the CSAW
Study in participating centres to obtain information on
the characteristics of recruitment into a mixed interven-
tion surgical trial (both surgical and nonsurgical treat-
ment groups). It will also identify sources of recruitment
difficulties (refer to Additional file 1). Anonymised feed-
back and suggestions will be provided to the Chief In-
vestigator (CI) and the Trial Management Group (TMG)
to improve the recruitment process, rates of randomisa-
tion and informed consent.
Objectives
The primary objective is to compare ASAD against a
nonsurgery arm (the AMSR group) to assess efficacy. In
addition, both ASAD surgery and AMSR will be separ-
ately compared with investigational shoulder arthros-
copy (the AO group) to delineate the mechanism of any
benefit. The primary outcome measure is the Oxford
Shoulder Score (OSS) at 6 months.
Secondary objectives include the comparison of the
three treatment arms in the CSAW Study with regards
to other variables—namely, cost-effectiveness, self-
reported outcomes (OSS) at 12 months, shoulder
function, range of motion, pain, complications, treat-
ment expectations and patient satisfaction, anxiety
and depression.
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Number of centres
Participants will be recruited at NHS hospitals throughout
the United Kingdom. An initial minimal set of centres (n =
14) is planned; however, if recruitment rate indicates the
need, the number of recruiting centres will be increased ac-
cordingly. The initial centres involved in the CSAW Study
are known to the study team from previous collaboration
in the United Kingdom Rotator Cuff Trial (UKUFF study;
ISRCTN97804283). Their contribution and recruitment
rates were reviewed in preparation for the CSAW Study
protocol.
Nonrandomised patients
Patients with subacromial pain who are eligible for trial par-
ticipation but do not want to be randomised owing to their
strong treatment preferences may still be included in a co-
hort substudy. With their consent, these patients will
complete a questionnaire regarding their treatment prefer-
ences, reasons for not wanting to participate in the trial and
a set of standard outcomes. This information may help with
the analysis of the feasibility data by indicating if and why
recruitment may be suboptimal or failing. It will also help
meet Consolidated Standards of Reporting Trials require-
ments and the design and implementation of future, related
studies. We anticipate recruiting up to 300 patients to this
‘preference-only’ part of the study. Questionnaires will be
coordinated by the central study office in Oxford.
Primary and secondary outcome measures
Primary outcome measure
The CSAW Study primary outcome measure is the OSS
at 6 months postrandomisation. The OSS is a patient-
based questionnaire and is a validated and effective
measure of change over time [39].
Secondary outcome measures
The following are the secondary outcome measures:
 OSS at 12 months postrandomisation
 Constant-Murley shoulder score: assesses shoulder
function and range of motion and is commonly used
by health care practitioners [40]
 PainDETECT: a patient-based screening questionnaire
used to predict the prevalence of neuropathic pain
components that has been widely used in many areas
of musculoskeletal care [41]
 Quantitative sensory testing: measures pain and pain
thresholds (This is a modified form of the full
quantitative testing and was validated by Gwilym et
al. in 2009 [42].)
 Complications during and after the treatment.
 EQ-5D: a measure of general quality of life
 Health service use: measures the cost utilisation
associated with the treatments
 Treatment expectations: Expectations will be
assessed using two different scores. The first score
was developed by Henn et al. [43] and is
calculated using the Treatment Expectations
Questionnaire. This questionnaire asks six general
questions about pain and function. More
shoulder-specific expectations will be predicted by
asking patients to state how they expect to feel
and function in 12 months’ time using the OSS.
 Patient satisfaction: Patient satisfaction will be
assessed using the Oxford Satisfaction Index. This
index includes transition questions developed and
used recently by members of the study team to
measure patients’ satisfaction after shoulder surgery
[44].
 Anxiety and depression: The Hospital Anxiety and
Depression Scale will be used to detect states of
depression and anxiety in the setting of a hospital
medical outpatient clinic [45].
The timing of all assessments is shown in Table 1 as a
schedule of events. It is acknowledged that there are
many outcome assessments, and questionnaire fatigue
may be an issue. This will be closely monitored. Poor re-
sponse rate to follow-up will be used as a marker of
questionnaire fatigue.
Study participants
Diagnosis of subacromial shoulder pain will be con-
firmed by a consultant surgeon. A clinical history and a
clinical examination will be completed by the recruiting
surgeons or members of their team. This will be done to
ensure that the symptoms and pain course are indicators
for arthroscopic surgery. Other possible shoulder diag-
noses, such as frozen shoulder, full-thickness rotator cuff
tears and instability, will be ruled out as much as clinical
diagnosis allows.
Inclusion criteria
 Subacromial pain of at least 3 months’ duration
(tendinopathy and partial tear only)
 Consultant’s clinical diagnosis of tendinopathic pain
or partial thickness rotator cuff tear (using local
pathways of diagnosis, which may include X-rays,
magnetic resonance imaging (MRI) scans or
ultrasounds)
 Eligible for arthroscopic surgery
 Completion of a conservative management
programme previously, including both:
Physiotherapy that includes a remedial exercise
regimen
At least one cortisone injection
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Exclusion criteria
The participant may not enter the study if any of the fol-
lowing apply:
 Full-thickness tear of the rotator cuff tendons or
calcific tendonitis evident on routine imaging
 Other shoulder pathology (non-impingement-
related) identified on MRI scan or ultrasound
 Undergone any of the following surgeries on the
affected shoulder:
ASAD
Cuff repair
Joint replacement
Surgery involving the glenohumeral joint (GHJ) in
the past 3 years
 Rheumatoid arthritis or any other inflammatory
disorder of the joints
 Symptomatic cervical spine pathology
 Previous septic arthritis in the shoulder only
 History of radiotherapy on same side as affected
shoulder
 Patients who:
Are unlikely to be able to perform the required
clinical assessment tasks
Have significant cognitive impairment or language
issues
Are unable to provide consent for themselves
 Older than 75 years of age
Study procedures
Recruitment organisation
Patients who would, in a routine care pathway, be con-
sidered for shoulder surgery for subacromial pain will be
identified in outpatient clinics. Consultant orthopaedic
surgeons and members of their teams will introduce the
study to the patients and refer them to a research nurse
and/or physiotherapist for further information. In all
cases, the consultant orthopaedic surgeon will approve a
patient’s eligibility for the study. Patients will be pro-
vided with written information about the study and
asked to opt in. If their interest continues, they will be
provided with further written information and arrange-
ments will be made for a baseline appointment for as-
sessment, consent and, in some situations, QRI
conversation analysis audiotaping. The baseline assess-
ment will be done as a separate appointment. These ar-
rangements will be individualised for each centre. A
reflection period for consent of at least 48 hours will be
given following introduction of the study, but it is pro-
posed that these appointments occur within 1 month of
the initial approach. Consent will be obtained for any
QRI-related audiotaping of appointments.
At the baseline appointment, patients will meet with a
member of the CSAW Study research team again to dis-
cuss the process and to discuss the study further. The
surgeon may also attend this visit to reiterate why the
study is being conducted. Patients will be asked to sign
an informed consent form, and baseline questions will
be completed. Patients will be recruited over a 36-
month period. Further details of the recruitment and
follow-up processes can be found in Additional file 2.
Randomisation
After written informed consent is obtained and patient
eligibility is confirmed, and immediately after the base-
line appointment, patients will be randomised into the
study by site staff authorised to perform telephone ran-
domisations. Randomisations will be performed centrally
by the Oxford Clinical Trials Research Unit within office
hours (8 AM to 5 PM), Mondays to Fridays, excluding
public and/or bank holidays. The following information
will be required at the randomisation call: participant
details, research site details, name of caller, name of
treating consultant, confirmation of eligibility, confirm-
ation of written informed consent and its date, and
stratification factors (see below).
Table 1 Timetable of assessmenta
Assessment Baseline 6 mo 1 yr 1 yr posttreatment
(for waiting list breachers only)
OSS (self-reported pain and function) ▲ ▲ ▲ ▲
Constant-Murley shoulder score ▲ ▲ ▲ ▲
QST and PainDETECT ▲ ▲ ▲ ▲
EQ-5D (health economics) ▲ ▲ ▲ ▲
Health service use ▲ ▲
Treatment expectations and patient satisfaction ▲ ▲ ▲ ▲
Complications N/A ▲ ▲ ▲
Patient response shift N/A N/A ▲ ▲
Hospital Anxiety and Depression Scale ▲ ▲ ▲ ▲
aN/A, Not applicable; OSS, Oxford Shoulder Score; Quantitative sensory testing. All information is postrandomisation, unless stated otherwise.
▲Outcome measure to be collected at this assessment.
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Patients will be allocated a study number and will be
randomised on a 1:1:1 basis to receive one of the three
treatment options: ASAD surgery, AO or AMSR.
Randomisation will be performed using an automated,
computer-generated minimisation system to ensure that
treatment groups are well balanced for the following pa-
tient characteristics, the details of which will be required
for the randomisation:
 Age (<40, 40 to 55 or 56+ years)
 Sex
 Baseline OSS (<19, 19 to 26, 27 to 33 or 34+)
 Centre
Surgery
Patients randomised to surgery will immediately be
placed on the waiting list for surgery, with the expect-
ation that surgery will be performed within 4 months.
This reflects the average current surgical waiting time in
the NHS. The surgical group to which the patient has
been allocated will be concealed from the surgical team
and revealed only on the day of planned surgery.
Active monitoring with specialist reassessment
Patients randomised to the AMSR group will receive a
letter stating that a specialist reassessment appointment
will be scheduled for a date 3 months hence. The re-
assessment will identify any patients who require adjust-
ment to their management.
Informed consent
Patients will be asked to opt in to the study before re-
ceiving further information and asked to attend a base-
line appointment. The opt-in form does not obligate the
patient to participate in the study, but it will allow mem-
bers of the CSAW Study team (both locally and cen-
trally) to contact them further. Full consent will be
obtained during the baseline visit by the participating
surgeon or by qualified local centre study staff. The
Principal Investigator at this centre will have overall re-
sponsibility for consenting patients, but can delegate the
task to reliable members of the study team. Such delega-
tion will be recorded on a Task and Responsibilities Log
during centre initiation. Informed consent will be ob-
tained according to Good Clinical Practice guidelines.
Patients will be given sufficient time to accept or decline
involvement. They will be free to withdraw from the
study at any time without affecting their routine care.
Patients who complete the opt-in form but decline to
be randomised may also be contacted in relation to the
CSAW Cohort Study and the QRI. Satellite studies asso-
ciated with the CSAW Study will have their own in-
formed consent process. These are detailed later in the
protocol.
Qualitative recruitment investigation
To characterise and understand the success or failure of
the CSAW Study recruitment process, the QRI findings
will be reviewed. These data will inform changes to as-
pects of the design, conduct and organisation of the trial
and future surgical trials and to provide training which
could potentially lead to improvements in recruitment.
All findings and any suggested changes are fed back first
to the CI and RCT staff involved in the TMG. Further
details of the CSAW Study QRI process can be found in
Additional file 1.
Study assessments
Participating surgeons will be asked to coordinate their
waiting lists to ensure the CSAW Study patients are
called for surgery in accordance with the study protocol.
Prestudy questionnaires have been designed to screen
sites for their ability to conform. Ideally, patients will
complete their baseline assessments as close to the
randomised treatment as possible (within 4 months).
However, owing to the expected variability inside the 4-
month window, and in the event of the unfortunate (but
quite possible) breach of this 4-month window in a mi-
nority of patients, contingency measures have been in-
corporated to maintain design integrity. In the event
that surgery cannot be performed within 4 months of
randomisation, the same questions and assessments
completed at baseline will be repeated. This assessment
will be performed within the 2 weeks leading up to the
patient’s operation (either on the day of surgery or at the
preoperative assessment appointment). This will high-
light any changes in the patient’s shoulder pain and
function.
Follow-up measurements will be conducted postran-
domisation. All patients will be followed up at 6 and 12
months postrandomisation, with patients in the AMSR
arm having their specialist reassessment at 3 months
postrandomisation. To capture the full effect of the
intervention, patients who are on surgical waiting lists
for longer than 4 months will have an additional 12-
month posttreatment assessment. Each follow-up point
will involve a clinical assessment, so patients will be
asked to attend hospital for an appointment. Clinical as-
sessments and questionnaires can be completed during
these visits. The attendance of patients for an appoint-
ment will also ensure that the patients allocated to the
nonoperative arm receive the specialist reassessment.
Compliance and loss to follow-up
We anticipate that 90% of patients will accept their allo-
cated treatment (no immediate crossover), and therefore
we have accounted for a dropout rate of 15% from the
entire study over time. These estimates are based on as-
sessments of our UKUFF study data. Compliance and
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withdrawals will be monitored as the CSAW Study pro-
gresses. The end of the study is set as the date of the last
follow-up visit of the last patient.
Study interventions
Patients randomised to surgery will remain unaware of
which procedure they have undergone (ASAD or AO).
The CSAW Study surgical procedures will mirror each
other. Both operations will be performed through two
arthroscopic keyholes. Standardised postoperative care
and rehabilitation will be applied for both groups (ASAD
and AO). If any unexpected pathology is encountered,
such as full-thickness rotator cuff tear, frozen shoulder
or arthritis, the patient will receive treatment for this
pathology while under the same anaesthetic. In such a
case, the participant will continue to be followed up for
the study. Preoperative imaging of the shoulder (ultra-
sound and MRI scan) is known not to be fully accurate
(inaccuracy rate of approximately 5%), and it is usual
practice to advise patients of this. As a consequence,
consent is routinely obtained in surgical settings for any
additional treatment that may be required if an unex-
pected pathology or problem is encountered. The
CSAW Study protocol dictates that when consent for
the surgery is taken, surgeons will inform patients that
they will be consented for shoulder arthroscopy, plus or
minus an arthroscopic subacromial decompression, plus
or minus a rotator cuff repair. This will ensure that pa-
tients are informed of the risks of surgery and potential
eventualities. Further details of the individual interven-
tions are given below.
Arthroscopic subacromial decompression
The procedure is performed with the patient under gen-
eral anaesthesia. Skin incisions are made for the intro-
duction of the arthroscope and required instruments.
The procedure involves insertion of the arthroscope into
the GHJ, where the joint surface is inspected along with
the intraarticular portion of the long head of biceps and
the joint surface of the rotator cuff tendons. Once this
has been performed, the arthroscope is removed and
inserted into the subacromial bursa, which lies outside
the rotator cuff tendons and beneath the acromion
process of the scapula. In the bursa, the acromion and
superior surface of the rotator cuff are assessed to en-
sure that the coracoacromial ligament and the AC joint
remain intact. The projecting undersurface of the distal
part of the acromion is resected. The intervention is
considered a well-established and well-documented
procedure.
Arthroscopy only
The AO arm is the surgical comparison group. The pro-
cedure is performed with the patient under general
anaesthesia. Patients will undergo a routine investiga-
tional arthroscopy of the joint and rotator cuff tendon.
The operation will be performed in exactly the same
manner as that in the ASAD group. Investigational arth-
roscopy has all the same essential operative components
(and risks) of ASAD, but it does not involve surgical re-
moval of any spurs or bursal tissue or release of the cor-
acohumeral ligament. The procedure does involve the
GHJ and the subacromial bursa being inspected and irri-
gated. Structures can be assessed for integrity and dam-
age. The rotator cuff can be assessed for evidence of
full-thickness tears. The synovium and lining of the
shoulder can be assessed for evidence of capsulitis, arth-
ritis or frozen shoulder. The time spent in the operating
theatre will be similar to that for the ASAD group.
These measures provide the AO group with the charac-
teristics necessary to provide a reasonable comparison
and account for the placebo effects of surgery.
Active monitoring with specialist reassessment
Patients will be advised that they will undergo active
monitoring. They will attend a reassessment appoint-
ment 3 months after entering the study. At that appoint-
ment, they will be asked to complete questionnaires
related to their shoulder pain and undergo a clinical as-
sessment of the shoulder, including a record of any fur-
ther conservative treatment. If, at the end of the 6-
month assessment period, patients remain sufficiently
symptomatic to require further intervention (based on
clinical judgement), then additional treatment options
will be discussed. It should be noted that the inclusion
criteria state that all patients will have undergone con-
servative treatment (including physiotherapy and injec-
tion) before entering the trial. From an ethical
standpoint, it is emphasised that it is quite within nor-
mal practice to have a period of active monitoring.
Blinding
Blinding is performed for both patients and postinter-
vention assessors in the surgical groups. For the AMSR
group, blinding of the postintervention assessors only is
appropriate and therefore will be applied. There will be
a nominated unblinded person at each participating site.
This person will be the main contact person for the pa-
tient and for the central study team in Oxford. Patients
will be encouraged to contact this person for queries, if
they have any complications and if they wish to pursue a
different treatment option.
Safety
There are no anticipated safety issues with the CSAW
Study. Data on complications will be recorded as out-
comes, and their severity and frequency will be assessed.
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Standard NRES safety reporting measures will be ad-
hered to.
CSAW Study complications
Expected complications in the CSAW Study are as
follows:
1. Frozen shoulder
2. Joint and/or soft tissue infection
3. Further shoulder surgery
Local study teams that identify any complications will no-
tify the CSAW Study office in Oxford. To maintain blind-
ing, further information about the complications will be
collected from the patients or the unblinded person at the
corresponding site. The CSAW Study team in Oxford will
coordinate collection of these data. Complications will be
deemed serious if they meet the criteria listed below.
Definition of serious adverse events
A serious adverse event (SAE) is any untoward medical
occurrence that
 Results in death
 Is life-threatening
 Note: The term life-threatening in the definition of
serious refers to an event in which the participant
was at risk of death at the time of the event; it does
not refer to an event which hypothetically might
have caused death if it were more severe.
 Requires inpatient hospitalisation or prolongation of
existing hospitalisation
 Results in persistent or significant disability and/or
incapacity or is a congenital anomaly/birth defect
 Other important medical events
Other events refers to any event that may not result in
death, is not life-threatening or does not require hospi-
talisation, but may be considered a serious adverse event
when, based upon appropriate medical judgment, the
event may jeopardise the participant’s health and may
require medical or surgical intervention to prevent one
of the outcomes listed above.
Reporting procedures for unexpected serious adverse
events
An unexpected serious adverse event (USAE) should be
reported to the REC that gave a favourable opinion of
the study when, in the opinion of the CI, the event is:
 Related (that is, it resulted from administration of
any of the research procedures)
 ‘Unexpected (that is, the type of event is not listed
in the protocol as an expected occurrence)
Reports of related SAEs and USAEs should be submit-
ted within 15 days of the CI’s becoming aware of the
event, using the NRES Report of Serious Adverse Event
Form (available from: http://www.dt-toolkit.ac.uk/
resourceindex/all.cfm).
Statistics and analysis
Target sample size
A total sample size of 300 patients is planned. For a bal-
anced three-group trial, this means that approximately
100 patients will be recruited per allocation group
(ASAD, AO and AMSR).
Sample size calculation
The sample size calculation is based on the primary out-
come measure, the OSS at 6 months postrandomisation.
Currently, there is no established minimal clinically
important difference (MCID) for the OSS. In the ab-
sence of this, an approximation to the MCID can be
based upon the change in the score between pre- and
posttreatment. One-half of the standard deviation
(SD) of this change could be viewed as an important
change. In previous studies, the SD of the change in
OSS has been estimated to be 9.0, giving a target dif-
ference of 4.5.
Using a two-sided t-test, 90% power to detect a differ-
ence in OSS of 4.5 (SD 9.0), with a two-sided 5% level of
significance (α), a sample size of 85 participants is
needed in each group. Accounting for dropouts and loss
to follow-up of up to 15%, 100 participants are required
in each group. Therefore, we aim to recruit a total of
300 participants (100 per treatment group) into the
CSAW RCT. No adjustment was made for multiple
comparisons.
Recruitment rate and access to the National Health Service
A total of 300 participants need to be recruited over 36
months. For 14 centres, this would mean an average re-
cruitment of 21 to 22 patients per centre over 3 years
(or approximately 7 patients per centre per year). As
one-third (approximately 7) of these will be allocated to
the AMSR group, the number of patients recruited for a
surgical procedure will be around 14. When considering
the availability of operating theatre time for this proced-
ure, 14 operations are considered entirely manageable
within 3 years. The addition of any further centres to the
trial would decrease the average number of operations
per centre required for the trial.
Analysis of endpoints
General considerations The statistical analysis of the
CSAW Study is the responsibility of the trial statistician.
A full statistical analysis plan will be written by the trial
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statistician and agreed upon by the independent Data
Monitoring Committee (DMC) before any analyses are
undertaken.
Baseline data will be compared to determine whether
there are any clinically important differences between
treatment groups that have occurred by chance. It is an-
ticipated that STATA statistical software (StataCorp,
College Station, TX, USA), or another validated statis-
tical software package such as SAS (SAS Institute, Cary,
NC, USA) or R (versions will be recorded in the Statis-
tical Report), will be used in the analysis.
All statistical testing will be performed at the two-
sided 5% significance level, and 95% confidence intervals
will be presented where appropriate. For all analyses, the
appropriate model assumptions will be verified, and al-
ternative methods will be used if more appropriate.
Prior to any analysis, any missing data pattern will be
investigated and reasons for missing data obtained and
summarised where possible. The primary analysis will be
conducted on the modified intention-to-treat analysis,
which includes all participants with nonmissing outcome
data, unless there is clear evidence that its underlying as-
sumption is inappropriate. Sensitivity analysis will be
performed to assess the robustness of the results by im-
puting missing data using multiple imputation under
both missing at random and missing not at random
assumptions.
Frequency of analysis A DMC will be set up to inde-
pendently review the data on safety, protocol adherence
and recruitment. Interim reports will be presented to
the DMC in strict confidence at a minimum of yearly in-
tervals. As no formal stopping rules have been specified
for this trial, no formal interim analyses are planned,
and hence no statistical testing will take place until the
final analysis. The final analysis will take place after all
participants have completed their follow-up and suffi-
cient time has been allowed for data entry and
validation.
Primary endpoint analysis The primary outcome
measure is the OSS measured at 6 months postrandomi-
sation. The treatment groups are ASAD, AO and AMSR.
Multivariate linear regression analysis (analysis of co-
variance (ANCOVA)) will be used to examine the effect
of the randomised intervention on the OSS at 6 months
postrandomisation using three separate two-way com-
parisons (that is, ASAD vs. AMSR, ASAD vs. AO, and
AO vs. AMSR). The model will be adjusted for (continu-
ous) baseline OSS, sex, age and other relevant patient
characteristics if appropriate. The minimisation factors
(excluding centre) which are of clinical importance will
be adjusted for in the model, regardless of statistical sig-
nificance. Transformation of skewed variables will be
considered, as will inclusion of polynomial terms if
appropriate.
In additional secondary analyses, we will investigate
the effect on the treatment estimates when long waiting
times before surgery are taken into account. Participants
with long waiting times before surgery may not yet have
reached their optimal point of recovery when assessed at
6 months postrandomisation, and their data may under-
estimate the true treatment effect of their intervention.
Analyses will include substituting the baseline and 6
months postrandomisation data for data collected at the
presurgery and six months postsurgery assessments, re-
spectively, for participants with a delay longer than 16
weeks before surgery. For participants with a long delay
before surgery, the 6 months postsurgery assessments
will coincide approximately with their 12 months post-
randomisation assessment.
Secondary endpoint analyses Linear regression analysis
(ANCOVA) will be used to examine the effect of the
randomised intervention on the OSS at 12 months post-
randomisation, using three two-way comparisons. The
model will be adjusted for appropriate baseline measure-
ments. In addition, a repeated-measures multilevel
model will be used, including repeated measures of the
OSS at 6 and 12 months (level 1) nested within partici-
pants (level 2). Adjustments will be made for the con-
tinuous baseline OSS, other relevant minimisation
factors and baseline measures as appropriate. Additional
supplementary analyses will take into account long wait-
ing times before surgery. As described for the primary
analysis, analyses will include substituting the baseline
and 12 months postrandomisation data for data col-
lected presurgery and at approximately 12 months post-
surgery, respectively, for participants with a delay longer
than 16 weeks before surgery. In sensitivity analyses, we
will look at the impact of a patient response shift on per-
ceived disability by comparing each patient’s preopera-
tive self-evaluation of his or her own disability (baseline
OSS) with a 12-month evaluation of perceived preinter-
vention state (the ‘thentest’) according to the method of
Razmjou et al. [46]. This analysis will give an indication
of whether patients with subacromial pain underrate or
overrate their preintervention disability according to
their outcome. The response shift will be presented de-
scriptively using medians, interquartile ranges and
ranges overall, as well as by treatment arm. The effect of
the response shift and perceived disability will be investi-
gated by refitting the above-described linear regression
model for the OSS at 12 months postrandomisation,
adjusting for continuous retrospective baseline OSS
(thentest), as well as other relevant minimisation factors
and baseline measures. Differences in the treatment ef-
fects using this approach and the previously described
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model for the analysis of the 12 months postrandomisa-
tion OSS will be highlighted.
The Constant-Murley shoulder score, PainDETECT,
quantitative sensory test, Hospital Anxiety and Depres-
sion Scale and EQ-5D (index score and Visual Analogue
Scale) measures will be scored according to their re-
spective scoring manuals. Linear regression analysis
(ANCOVA) will be used to analyse the 6- and 12-month
outcomes, respectively, and a repeated-measures multi-
level model will be fit (see above). The analysis will be
adjusted for the relevant minimisation factors and base-
line measures as appropriate.
Complications
Complications between the trial arms will be compared
in terms of frequency, seriousness and timing. To coin-
cide with the primary endpoint, complications occurring
within the initial 6 months from randomisation will be
summarised first; complications reported over the entire
duration of the trial will be reported separately. Logistic
regression analysis with covariate adjustment will be car-
ried out to test the difference in the proportion of partic-
ipants with at least one complication, given sufficient
events.
Treatment expectations and patient satisfaction
Treatment expectations will be summarised descriptively
using medians, interquartile ranges and ranges overall,
as well as by treatment arm. Patient satisfaction with
treatment will be summarised descriptively by treatment
arm for the 12-month time point. Cross-tabulations will
be generated to relate treatment expectations to treat-
ment satisfaction, and χ2 tests will be used to assess the
significance of the association.
Cost-effectiveness
The trial health economist will analyse the cost-
effectiveness of the three treatment arms. A specific plan
of analysis will be written for the health economics
analysis.
Qualitative recruitment investigation
Thematic analysis will be used to identify common and
emergent themes in the interview data by employing
constant comparison techniques until no new themes
emerge. Throughout the analysis, the perspectives of the
recruiters will be paramount. Content analysis will be
used to describe the terminology used by the recruiters
and compare this with written study information. Dis-
crepancies and areas of controversy will be identified
and explored. Conversation analysis will be used to in-
vestigate the delivery of information during the recruit-
ment appointments, with a particular focus on the
interaction between recruiter and patient (for example,
analysis of patient requests for clarification or places in
the conversation where pauses or other utterances dis-
rupt the smooth flow of interaction).
There will be frequent assessments of recruitment
rates—both randomisation and rates of compliance with
assigned treatment. These will be calculated for each of
the centres in which the QRI is running and across the
trial as a whole.
Ethics and participant confidentiality
The study has been designed under the ethical supervi-
sion of an academic ethicist (J.S.). The CSAW Study
does not include a true sham surgery treatment arm, but
it has comparisons that account for any placebo effects
expected with surgical procedures and will also allow de-
tailed assessment of the mechanism of effect. We are
satisfied that all potential ethical concerns have been ex-
plored and discussed and that the optimum route has
been taken, with patient welfare foremost but with study
validity taken into account.
The study staff will ensure that the participants’ ano-
nymity is maintained. The participants will be identified
only by initials and a participant identification number
on the Case Report Form and in any electronic database.
All documents will be stored securely and will be access-
ible only by study staff and authorised personnel. Tran-
scripts of all audio recordings will be anonymised, and
audio recordings will be labelled and stored with a pa-
tient code to protect participant anonymity. The study
will comply with the United Kingdom’s Data Protection
Act 1998, which requires data to be anonymised as soon
as it is practical to do so.
A DMC will be set up to independently review data on
safety, protocol adherence and recruitment in the
CSAW trial. Interim reports will be presented to the
DMC in strict confidence in at least yearly intervals.
This committee, in light of the interim data and any ad-
vice and evidence they wish to request, will if necessary
report to the Trial Steering Committee (TSC) if there
are any concerns regarding the safety of the trial treat-
ments. Although there are no formal stopping rules spe-
cified for the CSAW trial, the CSAW trial team,
together with the DMC, will closely examine the recruit-
ment of participants into the trial. If recruitment is low
compared with the specified targets, then reasons for
low recruitment will need to be explored and necessary
steps will need to be taken. Should it become clear that
potential participants refuse to consent into the trial be-
cause of an unwillingness to be randomised to the non-
treatment trial arm, recruitment and consent strategies
will need to be verified and if this should not result in
improved recruitment, then the AMSR trial arm may
have to be dropped.
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Data handling and record-keeping
Data management will be performed via a web-based trial
database (OpenClinica: http://www.openclinica.org/) and
managed by the Oncology Clinical Trials Office (OCTO).
OpenClinica is a dedicated and validated clinical trials
database designed for remote electronic data capture.
The CI will act as data custodian for the trial. A guide
explaining how to use OpenClinica will be provided to
every site. The CSAW Trial Coordinator and OCTO
monitors will have an overview of all entered data.
The participants will be identified by a study-specific
participant number and/or code in any database. The
name and any other identifying detail will not be in-
cluded in any study data electronic file. Any patient-
related data transferred between the main study office
and participating sites will be identifiable only with
each patient’s unique study number. If more identifiable
information is required, secure measures such as regis-
tered post, courier or nhs.net e-mail accounts will be
used. For quality control reasons, monitoring of site
files and data collection forms may be initiated by the
main study team.
Audio recordings will be stored on password-
protected devices provided by the University of Bristol
and transferred by recruiting centres on encrypted mo-
bile memory drives (pen drives). Codes for storing and
labelling patient and recruiter audio data will be gener-
ated by researchers at the University of Bristol once
written informed consent has been received from the
participants. Signed copies of informed consent forms
will be kept in a locked filing cabinet by researchers at
the University of Bristol. The CI will be held responsible
for their safe keeping.
Financing and insurance
The study is funded by Arthritis Research UK via a clin-
ical studies grant. The total grant is £332,389.76. The
University of Oxford has arrangements in place to pro-
vide for harm arising from participation in the study, for
which the university is the research sponsor. NHS in-
demnity operates in respect of the clinical treatment
which is provided. The University of Oxford has ar-
rangements in place to provide for nonnegligent harm
arising from participation in the study, for which the
University of Oxford is the research sponsor.
Publication policy
The trial investigators will be involved in reviewing
drafts of the manuscripts, abstracts, press releases and
any other publications arising from the study. Authors
will acknowledge that the study was funded by Arthritis
Research UK. Authorship will be determined in accord-
ance with the International Committee of Medical
Journal Editors guidelines, and other contributors will be
acknowledged.
Satellite studies
Separate protocols have been written that detail the re-
lated substudies. Any future satellite studies will have
their own protocols and their own consent forms.
CSAW neuroimaging observational study
Functional magnetic resonance imaging (fMRI) studies
of the brain will be included in the study to investigate
the neural correlates of the ASAD and compare them
with nontherapeutic diagnostic arthroscopy (the AO
group). fMRI is an objective tool used to assess under-
lying biological processes responsible for pain. fMRI uses
the same techniques as clinical MRI examinations. It is
noninvasive and safe, and it allows for repetitive mea-
surements in the same individual. fMRI has an advan-
tage over other imaging techniques in that it avoids
exposure to ionising radiation or radioactive tracers.
fMRI has been demonstrated to be an objective and sen-
sitive tool for assessment of the effect of therapeutic in-
terventions on pain in patients with chronic pain. This is
applicable only to patients recruited from Nuffield
Orthopaedic Centre, Oxford University Hospitals NHS
Trust, Oxford, UK.
CSAW tissue sample study
An analysis of tissue excised and routinely discarded
during ASAD will also be conducted. This includes
bursa, coracoacromial ligament and acromion bone tis-
sue. This proposed study will involve only one arm of
the study (ASAD) and not the other two (AO and
AMSR groups).
Small rotator cuff tears elicit a significant inflamma-
tory response which decreases as tear size increases [47];
however, relatively little is known about changes in the
neuronal signalling that occur in patients with subacro-
mial pain and rotator cuff degeneration. It has been
shown that substance P levels in the subacromial bursa
are significantly higher in patients with painful rotator
cuff tears [48], but the way in which inflammation and
painful tendon degeneration are affected by neuronal
signalling is poorly understood.
Our aim is to determine which neuronal and cell sig-
nalling changes occur during tendon degeneration, thus
furthering understanding of the key molecular mecha-
nisms involved in this process. Tissue from the subacro-
mial bursal area from patients in the ASAD group is
removed routinely as part of their surgical procedure.
Our aim is to analyse this tissue to investigate the rela-
tionship between variations in peripheral neuronal in-
nervation, nociceptor density, nerve growth factors and
clinical presentation with preoperative pain levels and
Beard et al. Trials  (2015) 16:210 Page 12 of 16
with outcome following surgery. A better understanding
of the key molecular processes involved in tendon de-
generation and shoulder pain also has the potential of
leading to novel therapeutics.
Discussion
As an innovative design and one that involves a placebo
surgical intervention, this trial protocol has several as-
pects that warrant further mention.
Intervention content
The intervention content for each of the groups was
carefully selected. The content of the ASAD was chosen
to represent what is most likely to be current practice
for this operation. Some level of consensus was obtained
by polling specialist society members (British Elbow &
Shoulder Society), but no formal confirmation of best
practice was obtained. It is suggested future trials might
formally define appropriate content for the best practice
surgical intervention. An AO intervention was deemed
ethical, as it is often considered an appropriate form of
surgical treatment for this condition, albeit mainly for
diagnostic and evaluation purposes. Likewise, a nonsur-
gical arm was considered ethical, as the inclusion criteria
required all patients to have undergone previous conser-
vative management. A nontreatment period is often ad-
vocated at this point in the pathway. Terminology was
important for the AMSR group. A group described as
having ‘no treatment’ would have been considered to
pose a threat to successful recruitment.
Identification of the critical surgical element
Careful consideration was given to ensuring that the
critical surgical element was identified and omitted for
the placebo intervention group (AO). Whilst this was
relatively straightforward for the CSAW Study (removal
of bone), it may not be quite so obvious for other surgi-
cal interventions which may have a more cumulative ef-
fect of the surgery.
Threats to recruitment
There are several aspects which need careful manage-
ment to avoid the potential for poor recruitment. Pa-
tients might perceive that two of the three options in
randomisation offer poor treatment alternatives. This
could result in a high rate of refusal to participate. Care-
ful wording and clear demonstration of the uncertainty
for all three intervention options was required. The in-
volvement and inclusion of an experienced qualitative
research team provides significant benefit by exploring
and addressing additional threats to recruitment. A fur-
ther threat to recruitment could have been lack of sur-
geon equipoise. Again, the qualitative work and repeat
demonstration of the uncertainty for practice, as well as
its efficacy, can help dispel worries and concerns among
the surgical investigators.
Crossover between groups
There is a concern that patients might cross over treat-
ment to surgery, especially among those in the active
monitoring arm. Clear procedures and thresholds for
clinical evaluation and crossover have been instigated to
prevent this. Whilst treatment cannot be withheld on
ethical grounds, patients are not actively encouraged to
explore alternative treatment options throughout the
study. The crossover rates of the control group to sur-
gery will also be reviewed, and the trial will be reconfi-
gured if needed.
Waiting list effects
It is rare that patients can undergo surgery after ran-
domisation without any delay, whereas those in the
AMSR group begin their intervention immediately.
Thus, waiting list effects can play a part in the study de-
sign and can introduce imbalance for follow-up times
between groups. To compensate, additional follow-up
assessments, referenced from surgery, have been intro-
duced for patients allocated to surgery. Patients waiting
for longer than 4 months for their surgery after random-
isation are termed breachers and given additional follow-
up appointments. The timing of these appointments
ensures their assessment is not done at a time that con-
flicts with any healing profile (that is, too early after sur-
gery) and is aligned to ensure appropriate comparison
with other patients. Note, all patients will undergo the
standard, scheduled 6- and 12-month postrandomisation
follow-up assessments, regardless of time to surgery.
Compliance and loss to follow-up
As the study follow-up (from baseline to primary end-
point) is only 6 months in duration, a very high level of
follow-up is anticipated based upon previous experience.
The number of assessments is not onerous for the pa-
tients and is spread out over 12 months. All attempts
will be made to make these appointments as convenient
for the patients as possible. The content of the assess-
ment is also not burdensome, with predominantly stand-
ard clinical measures being taken and examinations
being done. The assessments involve no discomfort for
the patient over and above the routine clinical shoulder
examinations. Although we do not expect any problems
with compliance, this will be monitored throughout the
trial. Patients who do not return follow-up question-
naires will receive reminder telephone calls. All possible
means to minimise the amount of missing data will be
employed. Refusal to participate and refusal to continue
with allocated treatment are considered to pose the big-
gest threats, particularly the active monitoring allocation.
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Both of these are dealt with by the contingency plan to
convert the trial to a two-arm trial upon completion of
the early review stage.
Interpretation
The importance of highlighting potential outcome and
the clinical implications has been shown by the develop-
ment of this trial. The complexities of the design mean
that interpretation is not straightforward. If surgery
(ASAD) were shown to be no more effective than
AMSR, then a question would hang over the continued
use of surgery for this condition in the NHS and in a
wider context. Conversely, if ASAD (or shoulder arth-
roscopy in general) is shown to be an effective treat-
ment, then the current enthusiasm for the procedure
should be encouraged and similar increased availability
within the health care system should be entertained. If
ASAD is more effective than AO, then it will have been
confirmed that it is necessary to remove an acromial
spur during arthroscopy. As a comparison of ASAD with
bursectomy alone has already been undertaken (showing
no difference at 1 year), the value of repeating this is not
apparent [27]. The difference in surgical morbidity and
cost is not likely to be significant between ASAD and
bursectomy alone. Clearly, there are health care eco-
nomic implications, and a full economic costing and cost
utility analysis will be performed for both types of
arthroscopy.
Trial status
The CSAW trial commenced in July 2012 and is on-
going. Recruitment was originally scheduled to end in
June 2014. Initial slow recruitment, mainly due to gov-
ernance issues and time taken to include and activate
additional recruiting centres, meant that recruitment
targets were not going to be met. An extension to the
trial was recommended by the TSC and DMC, which
was agreed upon by the funders. Completion of recruit-
ment is imminent.
Additional files
Additional file 1: Qualitative recruitment investigation.
Additional file 2: Study flowchart.
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